Seelos Therapeutics (SEELQ) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 07, 2014
Document Document And Entity Information [Abstract]	'	'
Document type	'10-Q	'
Amendment flag	'false	'
Document period end date	30-Jun-14	'
Document fiscal year focus	'2014	'
Document fiscal period focus	'Q2	'
Trading symbol	'APRI	'
Entity registrant name	'APRICUS BIOSCIENCES, INC.	'
Entity central index key	'0001017491	'
Current fiscal year end date	'--12-31	'
Entity filer category	'Accelerated Filer	'
Entity common stock, shares outstanding (in shares)	'	38,102,451

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$17,420	$21,405
Accounts receivable	49	59
Restricted cash	382	332
Inventories	377	336
Prepaid expenses and other current assets	605	132
Total current assets	18,833	22,264
Property and equipment, net	1,347	955
Other long term assets	105	91
Total assets	20,285	23,310
Current liabilities	'	'
Convertible notes payable, net	1,181	2,600
Trade accounts payable	1,128	926
Accrued expenses	1,807	2,119
Accrued compensation	758	952
Deferred revenue	2,000	1,800
Derivative liability	95	517
Deconsolidation of former French Subsidiaries	0	2,846
Total current liabilities	6,969	11,760
Long term liabilities	'	'
Deferred compensation	400	487
Deferred revenue	1,000	0
Other long term liabilities	69	91
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2014 or December 31, 2013	0	0
Common stock, $.001 par value, 75,000,000 shares authorized, 38,102,451 and 37,541,404 issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	38	38
Additional paid-in-capital	281,260	279,000
Accumulated deficit	-269,451	-268,066
Total stockholders’ equity	11,847	10,972
Total liabilities and stockholders’ equity	$20,285	$23,310

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (USD per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock issued (in shares)	0	0
Preferred stock shares outstanding (in shares)	0	0
Common stock, par value (USD per share)	$0.00	$0.00
Common stock shares authorized (in shares)	75,000,000	75,000,000
Common stock, issued (in shares)	38,102,451	37,541,404
Common stock, outstanding (in shares)	38,102,451	37,541,404

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
License fee revenue	$5,454	$637	$5,454	$669
Contract service revenue	0	555	0	1,452
Total revenue	5,454	1,192	5,454	2,121
Cost of revenue	75	702	75	2,553
Gross profit (loss)	5,379	490	5,379	-432
Costs and expenses	'	'	'	'
Research and development	2,103	1,535	3,547	2,948
General and administrative	2,877	3,754	5,936	7,580
Gain on contract settlement	0	0	-910	0
Deconsolidation of former French Subsidiaries	-846	-641	-846	-641
Recovery on sale of subsidiary	0	-105	-50	-105
Total costs and expenses	4,134	4,543	7,677	9,782
Income (loss) from continuing operations before other income (expense)	1,245	-4,053	-2,298	-10,214
Other income (expense)	'	'	'	'
Interest expense, net	-69	-213	-176	-444
Other income (expense), net	29	180	417	-378
Total other income (expense)	-40	-33	241	-822
Income (loss) from continuing operations	1,205	-4,086	-2,057	-11,036
Income (loss) from discontinued operations	672	151	672	-1,572
Net income (loss)	$1,877	($3,935)	($1,385)	($12,608)
Net income (loss) per share from continuing operations	'	'	'	'
Net income (loss) per share from continuing operations, basc (USD per share)	$0.03	($0.12)	($0.06)	($0.35)
Net income (loss) per share from continuing operations, diluted (USD per share)	$0.03	($0.12)	($0.06)	($0.35)
Net income (loss) per share from discontinued operations	'	'	'	'
Net income (loss) per share from discontinued operations, basic (USD per share)	$0.02	$0	$0.02	($0.05)
Net income (loss) per share from discontinued operations, diluted (USD per share)	$0.02	$0	$0.02	($0.05)
Net income (loss) per share	'	'	'	'
Net income (loss) per share, basic (USD per share)	'	'	($0.04)	($0.40)
Net income (loss) per share, diluted (USD per share)	$0.05	($0.12)	($0.04)	($0.40)
Weighted average shares outstanding	'	'	'	'
Weighted average shares outstanding, basic (in share)	37,901	32,825	37,886	31,509
Weighted average number of shares outstanding, diluted (in shares)	37,907	32,825	37,886	31,509

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2012
Cash flows from operating activities of continuing operations:	'	'	'
Net income (loss)	($1,385)	($12,608)	'
Income (loss) from discontinued operations	672	-1,572	'
Net loss from continuing operations	-2,057	-11,036	'
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities of continuing operations:	'	'	'
Deconsolidation of former French Subsidiaries	-846	-641	'
Gain on contract settlement	-910	0	'
Depreciation and amortization	40	41	'
Accretion of debt discount	106	148	'
Stock-based compensation expense	1,036	1,238	'
Derivative liability revaluation	-422	375	'
Interest on contingent consideration	0	174	'
Recovery on loss on sale of subsidiary	-50	-105	'
Other	0	80	'
Changes in operating assets and liabilities of continuing operations:	'	'	'
Accounts receivable	10	-370	'
Inventories	-41	-249	'
Prepaid expenses and other current assets	-473	13	'
Other assets	-14	0	'
Accounts payable	202	-386	'
Liabilities associated with deconsolidation of Former French Subsidiaries	-2,000	0	'
Deferred revenue - short-term	200	-715	'
Accrued expenses and other current liabilities	-298	516	'
Accrued compensation	-194	-647	'
Deferred revenue - long-term	1,000	0	'
Deferred compensation	-87	-100	'
Other liabilities	-19	158	'
Net cash used in operating activities from continuing operations	-4,817	-11,506	'
Cash flows from investing activities of continuing operations:	'	'	'
Purchase of fixed assets	-432	-116	'
Deposit of restricted cash	0	-280	'
Proceeds from sale of subsidiary	50	105	'
Proceeds from the sale of property and equipment	0	3,657	'
Net cash (used in) provided by investing activities from continuing operations	-382	3,366	'
Cash flows from financing activities of continuing operations:	'	'	'
Issuance of common stock, net of offering costs	2,176	16,612	'
Repayment of principal on note payable	-1,525	0	'
Deposit of restricted cash	-50	0	'
Retirement of restricted stock	42	0	'
Repayment of capital lease obligations	-17	-25	'
Proceeds from exercise of warrants	0	46	'
Net cash provided by financing activities from continuing operations	542	16,633	'
Cash flows from discontinued operations:	'	'	'
Net cash used in operating activities of discontinued operations	-3	-359	'
Net cash provided by investing activities of discontinued operations	675	1,500	'
Net cash provided by discontinued operations	672	1,141	'
Net (decrease) increase in cash and cash equivalents	-3,985	9,634	'
Cash and cash equivalents, beginning of period	21,405	15,130	'
Cash and cash equivalents, end of period	17,420	24,764	15,130
Non-cash investing and financing activities:	'	'	'
Issuance of 486,923 shares of common stock upon conversion of convertible note	0	1,737	'
Release of obligations related to short-term loans	0	'	270
Topotarget Incorporated	'	'	'
Non-cash investing and financing activities:	'	'	'
Issuance of 148,441 shares of common stock to TopoTarget	$0	$387	'

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	6 Months Ended
	Jun. 30, 2013
Issuance of common stock upon exercise of convertible notes (shares)	486,923
Topotarget Incorporated	'
Stock issued during the period (shares)	148,441

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
December 31, 2013 at Dec. 31, 2013	$10,972	$38	$279,000	($268,066)
Balance as of December 31, 2013 (shares) at Dec. 31, 2013	'	37,541,404	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Issuance of restricted stock to employees and Board of Director members (in shares)	'	14,228	'	'
Retirement of restricted stock (in shares)	'	-19,338	'	'
Retirement of restricted stock	-42	'	-42	'
Stock-based compensation expense	1,036	'	1,036	'
Issuance of common stock, net of offering costs (shares)	'	955,045	'	'
Issuance of common stock, net of offering costs	2,176	'	2,176	'
Return of common stock in connection with contract settlement (in shares)	'	-388,888	'	'
Return of common stock in connection with contract settlement	-910	'	-910	'
Net loss	-1,385	'	'	-1,385
Balance as of June 30, 2014 at Jun. 30, 2014	$11,847	$38	$281,260	($269,451)
Balance as of June 30, 2014 (shares) at Jun. 30, 2014	'	38,102,451	'	'

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	Financial Statement Presentation
	The accompanying unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in Apricus Biosciences, Inc.’s (the “Company”) Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2014. The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying consolidated financial statements. Certain prior year items in the statement of cash flows have been reclassified to conform to the current year presentation. The consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The consolidated financial statements (unaudited) for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.
	Liquidity
	The accompanying unaudited consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $269.5 million as of June 30, 2014, recorded a net loss of approximately $1.4 million for the six months ended June 30, 2014, and has principally been financed through the public offering of the Company’s common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development. Funds raised in recent periods from the sale of common stock include approximately $15.8 million from the Company’s May 2013 follow-on public offering. Additionally, the Company raised approximately $2.2 million during the six months ended June 30, 2014 from the sale of common stock via its “at-the-market” (“ATM”) stock selling facility and approximately $0.8 million from this facility in 2013. In 2013, the Company divested certain non-core assets for net cash consideration of approximately $8.0 million primarily related to the sale of its New Jersey facility, the sale of its Totect® assets, and the sale of securities from an investment previously held. The Company also received $1.8 million in 2013 as an up-front payment from Laboratoires Majorelle (“Majorelle”). These and other cash-generating activities should not necessarily be considered an indication of the Company’s ability to raise additional funds in the future.
	The Company’s cash and cash equivalents as of June 30, 2014 were approximately $17.4 million. During the first half of 2014, the Company received an up-front license payment of $2.0 million from Hexal AG, a regulatory milestone payment of $0.2 million from Majorelle related to marketing approval obtained in France for Vitaros®, an up-front license payment of $2.5 million from Recordati Ireland Ltd. (“Recordati”) and $0.7 million from Samm Solutions, Inc. dba BioTox Sciences (“BioTox”). These cash inflows were offset by principal cash payments of approximately $1.525 million plus accrued interest made by the Company to holders of its convertible notes who exercised their redemption rights in the second quarter of 2014.
	Based upon its current business plan, the Company believes it has sufficient cash to fund its on-going operations into the second quarter of 2015. The Company expects to have net cash outflows from operations during the remainder of 2014 as it continues to support the market approvals and partner commercialization plans for Vitaros®, further develops Room Temperature Vitaros® and initiates a Phase 2a development program for RayVa™, its product candidate for the treatment of Secondary Raynaud’s Phenomenon. During the fourth quarter of 2014, the Company expects to make the final principal payments of $1.225 million of convertible notes (see Note 5), which mature on December 31, 2014. The Company expects the majority of its cash inflows from operations during the remainder of 2014 will be from licensing, and milestone revenues received from existing and potentially new commercial partners for licenses granted for Vitaros®. The Company also expects cash inflows to include royalty payments from the sale of Vitaros® by the Company’s partners in approved territories, sales of which began late in the second quarter of 2014 in the United Kingdom. The initial royalty amounts are not expected to be significant in the second half of 2014 as the product sales by partners will only be initiated during the second half of 2014.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity or convertible debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
	Segment Information
	The Company operates under one segment which designs and develops pharmaceutical products using its NexACT® technology.
	Net Income Per Share
	The Company reports diluted net income per share under the treasury stock method. Basic net income per share under the treasury stock method is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares may include stock options, restricted stock or shares related to convertible notes. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation expense and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.
	The following table sets forth the computation of basic and diluted EPS for the three and six months ended June 30, 2014 and 2013 (in thousands, except per share data):
		Three Months Ended June 30,					Six Months Ended June 30,
		2014		2013			2014			2013
	Basic net income (loss) per share
	Net income (loss) allocated to common stockholders	$	1,877	$	(3,935	)	$	(1,385	)	$	(12,608	)
	Weighted average common shares outstanding- basic	37,901		32,825			37,886			31,509
	Net income (loss) per share- basic	$	0.05	$	(0.12	)	$	(0.04	)	$	(0.40	)
	Diluted net income (loss) per share
	Net income (loss) allocated to common stockholders	$	1,877	$	(3,935	)	$	(1,385	)	$	(12,608	)
	Weighted average common shares outstanding- basic	37,901		32,825			37,886			31,509
	Dilutive securities	6		—			—			—
	Weighted average common shares outstanding- diluted	37,907		32,825			37,886			31,509
	Net income (loss) per share- diluted	$	0.05	$	(0.12	)	$	(0.04	)	$	(0.40	)
	Approximately 3.2 million stock options and restricted shares, 6.2 million warrants and 0.5 million convertible notes were excluded from the calculation of the denominator for diluted net income per common share for the three months ended June 30, 2014 due to their anti-dilutive effects. Share-based payment awards that are contingently issuable upon the achievement of a specified market or performance condition are included in our diluted earnings per share calculation only in the period in which the condition is satisfied. Of the 0.4 million performance options issued, none were included in the computation of diluted EPS as the performance conditions were not met as of June 30, 2014.
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and can be applied either prospectively or retrospectively to all awards outstanding as of the beginning of the earliest annual period presented as an adjustment to opening retained earnings. Early adoption is permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in the way it expects to be entitled for the transfer of promised goods or services to customers.  This ASU will replace most of the existing revenue recognition requirements in U.S. GAAP when it becomes effective.  This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted.  The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This ASU raises the threshold for a disposal to qualify as discontinued operations and requires new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation.  Under the new standard, companies report discontinued operations when they have a disposal that represents a strategic shift that has or will have a major impact on operations or financial results.  This update will be applied prospectively and is effective for annual periods, and interim periods within those years, beginning after December 15, 2014.  Early adoption is permitted provided the disposal was not previously disclosed.  This update will not have a material impact on the Company's reported results of operations and financial position.

Licensing_and_Research_and_Dev

Licensing and Research and Development Agreements	6 Months Ended
	Jun. 30, 2014
Disclosure - Licensing and Research and Development Agreements [Abstract]	'
Licensing and Research and Development Agreements	'
	Licensing and Research and Development Agreements
	Vitaros®
	Abbott Laboratories Limited
	In January 2012, the Company entered into an exclusive license agreement with Abbott Laboratories Limited (“Abbott”), granting Abbott the exclusive rights to commercialize Vitaros® for erectile dysfunction (“ED”) in Canada. The product was approved by Health Canada in late 2010. Under the license agreement, the Company received $2.5 million in October 2012 as an up-front payment. The Company determined that the only deliverable was the license element and given no additional obligation was associated with the license, the up-front license fee of $2.5 million from Abbott was recorded as revenue in the third quarter of 2012.
	Over the term of the agreement, the Company is eligible to receive an additional $13.2 million in aggregate milestone payments if all the regulatory and sales thresholds specified in the agreement are achieved, plus tiered royalty payments based on Abbott’s sales of the product in Canada.
	Bracco SpA
	On December 22, 2010, the Company entered into an exclusive license agreement with Bracco SpA (“Bracco”), granting Bracco the exclusive rights to commercialize Vitaros® product for ED in Italy. The product was granted national phase approval in Italy for the treatment of patients with ED in November 2013. Under the license agreement, the Company received $1.0 million as an up-front payment during the year ended December 31, 2011, and is eligible to receive up to €4.75 million ($6.5 million as of June 30, 2014), net of withholding taxes, in regulatory and sales milestone payments. Further, over the life of the agreement, the Company is eligible to receive tiered double-digit royalties based on Bracco’s sales of the product.
	The Company concluded that the only deliverable was the license element, and $0.3 million of the $1.0 million up-front payment was contingent upon the Company receiving regulatory marketing approval for the product in Europe. Therefore, $0.7 million, net of withholding taxes, was recognized as license revenue during the year ended December 31, 2011, as there was no additional obligation associated with the license. The remaining $0.3 million was deferred until the Company received regulatory marketing approval for the product in Europe, which occurred during the second quarter of 2013. Under the license agreement, an additional regulatory milestone of approximately $0.3 million was earned upon European regulatory approval in the second quarter of 2013 and as a result, approximately $0.3 million was billed and recognized as revenue for this substantive milestone during the second quarter of 2013, for a total of approximately $0.6 million of revenue recognized during the second quarter of 2013.
	Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies
	In February 2012, the Company entered into an exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”) for Sandoz to market Vitaros® for the treatment of ED in Germany. Under the license agreement, the Company received $0.7 million as an up-front payment and is eligible to receive up to an additional €0.4 million ($0.5 million as of June 30, 2014) in regulatory milestones and €20.875 million ($28.5 million as of June 30, 2014) in aggregate sales milestones if all the regulatory and sales thresholds specified in the agreement are achieved, as well as tiered double-digit royalties on net sales by Sandoz in Germany. The Company concluded that the only deliverable was the license element and given no additional obligation was associated with the license, the up-front license fee of $0.7 million, net of withholding taxes, from Sandoz for the German territory was recorded as revenue in the first quarter of 2012.
	In December 2013, the Company amended and restated its license agreement with Sandoz to include the following countries as part of the exclusive license agreement: Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the “Expanded Territory”). Under the revised agreement, the Company received in January 2014 an additional up-front payment of $2.0 million for the Expanded Territory, and is eligible to receive up to an additional $2.5 million in marketing launch milestones as well as €20.875 million ($28.5 million as of June 30, 2014) in sales milestones plus tiered double-digit royalties on net sales by Sandoz in the Expanded Territory as well as those milestones and royalties related to Germany specified above. Under the terms of the agreement, Sandoz is entitled to a refund of the up-front payment under certain regulatory and manufacturing conditions and, in accordance with the accounting guidance, the $2.0 million up-front payment has been deferred and will be recognized as revenue once the conditions related to the refund rights have been met or lapse. The results of the manufacturing and regulatory conditions are expected to be determined no later than December 2014 and December 2016, respectively.
	In 2013, Germany's Federal Institute for Drugs and Medical Devices, the Netherlands’ Medicines Evaluations Board and Sweden’s National Board of Health and Welfare each granted national phase approval to Vitaros® indicated for the treatment of patients with ED. Then, in January and April 2014, respectively, Belgium’s Ministry of Social Affairs, Public Health and Environment and the Ministry of Health of Luxembourg each granted national phase approval to Vitaros® indicated for the treatment of patients with ED. In August 2014, Sandoz launched Vitaros in Sweden, which triggered a launch milestone payment from Sandoz to the Company of $0.5 million.
	In July 2011, the Company filed a marketing application in Switzerland with Swissmedic, the Swiss Agency for Therapeutic Products, for Vitaros® as a treatment for patients with ED. The Swiss regulatory comments for the marketing approval of Vitaros® are expected in the second half of 2014, following a non-approval decision, appeal by the Company and a subsequent notice of re-review received in early 2014.
	Laboratoires Majorelle
	In November 2013, the Company entered into an exclusive license agreement with Majorelle, granting Majorelle the rights to commercialize Vitaros® for the treatment of ED in France, Monaco and certain countries in Africa. In December 2013, France's National Agency for Medicines and Health Products Safety granted national phase approval to Vitaros® indicated for the treatment of patients with ED. The Company received $1.8 million in November 2013 as an up-front payment, $0.2 million in January 2014 upon the receipt of marketing authorization in France, and is eligible to receive up to $2.0 million in additional regulatory milestone payments. Under the agreement, the Company is also entitled to €15.5 million ($21.2 million as of June 30, 2014) in sales milestones as well as tiered double-digit royalties based on Majorelle’s sales of the product.
	In December 2013, in a related negotiation, Majorelle agreed to make severance payments to certain former employees of Scomedica SAS for an aggregate amount of approximately $2.0 million on behalf of the Company. The Company concluded that the fair value of the Vitaros® license granted was equal to $4.0 million, or the sum of the $1.8 million upfront payment received, the $0.2 million payment received for National Phase approval in France, and the $2.0 million paid by Majorelle on behalf of the Company.
	During the second quarter of 2014, upon withdrawal of the Works Council Claim in June 2014 (see note 3 for further details regarding the claim), the Company recognized $3.0 million of the $4.0 million Vitaros® license fair value in license fee revenue in its statement of operations. Under the terms of the license agreement, Majorelle is entitled to a refund of $1.0 million of the upfront payment under certain contractual conditions. The $1.0 million subject to refund has been deferred and will be recognized as revenue once the condition related to the refund right has been met, which is expected to occur in 2014.
	Recordati Ireland Ltd.
	In February 2014, the Company entered into an exclusive license agreement with Recordati to market Vitaros® for the treatment of ED in Spain, Ireland, Portugal, Greece, Cyprus, the CEE Countries (Central and Eastern Europe), Russia and the other CIS Countries (former Soviet republics), Ukraine, Georgia, Turkey and certain countries in Africa. The Company received $2.5 million as an up-front payment in February 2014 and is eligible to receive up to €1.0 million ($1.4 million as of June 30, 2014) in commercial launch payments and €34.5 million ($47.1 million as of June 30, 2014) in sales milestones. Further, over the life of the agreement, the Company is entitled to receive tiered double-digit royalties based on Recordati’s sales of the product.
	Under the terms of the license agreement, there were two deliverables: the granting of a license and the execution of a Manufacturing Supply Agreement (the “Supply Agreement”). In accordance with the accounting guidance, the $2.5 million up-front payment was deferred when received in February 2014 until both deliverables were met. Upon execution of the Supply Agreement in June 2014, the Company satisfied the deliverables requirement under the terms of the license agreement and therefore recognized the full upfront payment as revenue during the second quarter of 2014.
	Two of the primary territories licensed by Recordati have been granted national phase approval. In August 2013, the Irish Medicines Board granted national phase approval to Vitaros® indicated for the treatment of patients with ED. Then, in April 2014, the Spanish Agency for Medicines and Health Products (“AEMPS”) granted national phase approval to Vitaros® indicated for the treatment of patients with ED.
	Takeda Pharmaceuticals International GmbH
	In September 2012, the Company entered into an exclusive license agreement with Takeda Pharmaceuticals International GmbH (“Takeda”) to market the Company’s Vitaros® drug for the treatment of ED in the United Kingdom. In August 2013, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency granted national phase approval to Vitaros® indicated for the treatment of patients with ED. Under the license agreement, the Company is eligible to receive up to €34.65 million ($47.3 million as of June 30, 2014) in up-front license fees and aggregate milestone payments if all the regulatory and sales thresholds specified in the agreement are achieved, plus tiered double-digit royalty payments. The agreement with Takeda includes two deliverables: the granting of a license and manufacturing, with related product supply. In accordance with the accounting guidance on revenue recognition for multiple-element agreements, the product supply element of the agreement meets the criteria for separation. Given there was no additional obligation associated with the license element, the up-front license fee of $1.0 million from Takeda was recognized as revenue in the third quarter of 2012.
	Actavis plc
	In 2012, the Company entered into a supply and testing agreement with Warner Chilcott UK Limited, a subsidiary of Actavis plc (Warner Chilcott UK and Warner Chilcott Company Inc. collectively referred to herein as “Actavis”), to supply and provide testing services related to Vitaros®. The Company determined that the agreement with Actavis included two deliverables: certain contract services and product supply. The product supply element and contract services element of the agreement were treated as separate units of accounting. No revenue was recognized associated with the product supply element. Revenue associated with the contract services element was fully recognized in 2013 using the proportional performance method over the period in which the contract services were performed.
	Actavis acquired the Vitaros® United States (“U.S.”) commercial rights in 2009. The Company believes that there is a significant commercial opportunity for Vitaros® in the U.S. and is in discussions with Actavis to explore the various options available to advance the Vitaros® clinical development program forward in the U.S.

Ceased_Operations_and_Disconti

Ceased Operations and Discontinued Operations (Notes)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Ceased Operations and Discontinued Operations	'
	Ceased Operations and Discontinued Operations
	Former French Subsidiaries
	On April 25, 2013, certain of the Company’s former French subsidiaries, Scomedica SAS, NexMed Europe SAS and NexMed Pharma SAS (the “French Subsidiaries”) entered into a judicial liquidation procedure as a result of a decrease in the unit’s operating performance resulting from the then recently enacted pricing policies affecting drug reimbursement in France, the subsequent related loss or interruption of certain contract sales agreements and in this context, the Company’s decision to cease financing its former French Subsidiaries.
	In June 2013, the Versailles Civil Court (the “Civil Court”) authorized the French Works Council (representing individuals previously employed by the former French Subsidiaries) to deliver a writ of summons to the Company for a hearing in the Civil Court in September 2013. In the summons it was claimed that the Company was the co-employer of the individuals working for Scomedica SAS and that, as such, was liable for the financing of a job protection plan. The summons sought €4.1 million ($5.6 million as of June 30, 2014) from the Company.
	In November 2013, the Company entered into a license agreement with Majorelle for certain territories including France (See note 2 for more details). In February 2014, a Global Settlement Agreement (“GSA”) by and among the Company, the Works Council and the Judicial Liquidator and Trustee of the Company’s former French Subsidiaries (collectively referred to herein as the “Parties to the GSA”), was ratified by the Versailles Commercial Court (the “Commercial Court”). In April 2014, the Company and the former French Subsidiaries’ employees executed individual settlement agreements.
	Pursuant to the aforementioned license and settlement agreements, Majorelle agreed to make certain severance payments of approximately $2.0 million to the former French Subsidiaries’ employees on behalf of the Company, a portion of which were made in May 2014. In addition, the Parties to the GSA as well as each of the former French Subsidiaries’ employees waived all claims they had asserted or could have asserted against the Company related to the liquidation and reorganization of the French Subsidiaries. In June 2014, consistent with the GSA, the Works Council withdrew its previously submitted €4.1 million claim in the Civil Court, all parties accepted the withdrawal and the Civil Court judge closed the discussions between all parties. The final step, which is perfunctory in nature, is scheduled on October 7, 2014, with a written judgment expected approximately six weeks later, during which the Civil Court is to acknowledge the dismissal of the claim and the closure of the litigation. Given the existence of the aforementioned ratified GSA, the accepted withdrawal and the closure of the discussions by the Civil Court judge, it is concluded that the Company is relieved of all claims previously asserted by the French Works Council.
	As a result, during the second quarter of 2014, the Company released the approximate $2.8 million liability previously recorded in connection with the deconsolidation of the former French Subsidiaries and recognized approximately $0.8 million as a gain on deconsolidation as follows:
	Release of deconsolidation liability	$	2.8
	Less: Payments made by Majorelle and recorded as settlement payment charge by the Company	(2.0		)
	Gain on deconsolidation of former French Subsidiaries	$	0.8
	In addition, the Company recognized $3.0 million of the $4.0 million license value (see note 2 for more details) as license fee revenue in its statements of operations in the second quarter of 2014. Under the terms of the license agreement, Majorelle is entitled to a refund of $1.0 million of the upfront payment under certain contractual conditions. The $1.0 million subject to refund has been deferred and will be recognized as revenue once the condition related to the refund right has been met, which is expected to occur in 2014.
	Sale of Bio-Quant
	During June 2011, the Company sold all of the outstanding capital stock of Bio-Quant, to BioTox. Bio-Quant provides contract research services to third-parties. The Company received $0.5 million at the transaction date as an initial payment. As a result of the sale, the Company was entitled to receive earn-out payments calculated as a percentage of the future gross revenue of BioTox’s contract research organization services business. Over the ten-year term of the earn-out, beginning September 2012, the Company was entitled to receive minimum payments of $4.5 million at a rate of $0.5 million per year, with the right to receive additional amounts depending on the gross revenue of BioTox over this ten-year period.
	Due to the uncertainty associated with the consideration due from BioTox, future minimum payments were not recognized as a receivable as of the sale date. In each of 2013 and 2012, the Company received $0.3 million in payments from Bio-Quant, which were recorded as recoveries of the loss recorded on the sale of subsidiary.
	In June 2014, the Company and Biotox amended its stock purchase agreement and the Company received a one-time cash payment of approximately $0.6 million during the second quarter of 2014, in exchange for relinquishing its rights to minimum payments in the future. Prior to the amendment of the agreement, the Company also received payments of approximately $0.1 million for a total received from Biotox of $0.7 million in 2014. The Company also has rights to certain potential future payments upon a change of control of Biotox within a specified time frame. These potential future payments will be recorded when realized.
	The Company has recorded the gain of approximately $0.7 million as discontinued operations within its statement of operations during the three and sixth months ended June 30, 2014. Historically, the Company reflected the operations and subsequent cash collections associated with the sale of the business as a component of continuing operations, on the line recovery on sale of subsidiary within the consolidated statement of operations. However, the Company has elected to not correct these amounts which are deemed inconsequential.

Other_Financial_Information

Other Financial Information	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Other Financial Information	'
	Other Financial Information
	Inventory
	Inventory is comprised of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	160	$	209
	Work in process	116		127
	Finished goods	101		—
	Inventory, net	$	377	$	336
	Inventories are valued at the lower of cost (first-in, first-out) or market value (net realizable value) considering excess and obsolete inventory based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life and assumptions about the likelihood of obsolescence.
	Accrued expenses
	Accrued expenses are comprised of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Professional fees	$	692	$	997
	Outside research and development services	474		298
	Deferred compensation	175		184
	Environmental remediation services	146		168
	Other	320		472
		$	1,807	$	2,119
	Pursuant to the March 2013 sale of its New Jersey facility, the Company has $0.3 million of restricted cash held in escrow for environmental remediation services to be performed and for property taxes, both of which are the obligation of the Company. The Company has recorded a liability for the environmental remediation as well as tax liabilities, which represent the best estimate of the total obligations and are expected to be satisfied within the current year and are therefore classified as current restricted cash and current liabilities, respectively.

Convertible_Notes_Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Convertible Notes Payable	'
	Convertible Notes Payable
	On December 7, 2012, the Company issued convertible notes (the “2012 Convertible Notes”). The 2012 Convertible Notes are, at the holders’ option, redeemable in cash upon maturity at December 31, 2014, or convertible into shares of common stock at a conversion price ($2.58 per share as of June 30, 2014), which is subject to adjustment upon certain dilutive issuances of common stock. The 2012 Convertible Notes bear interest at 7% per annum, which is payable quarterly.
	The fair value of the 2012 Convertible Notes was determined based on a discounted cash flow model using a risk adjusted annual interest rate of approximately 16%, which represents a Level 3 measurement within the fair value hierarchy given that this is an unobservable input. The fair value of these notes as of June 30, 2014 approximates the book value. In accordance with the terms of the 2012 Convertible Notes, the holders redeemed $1.525 million of the principal on April 1, 2014, plus accrued interest. As of June 30, 2014, the remaining principal balance is $1.225 million and at the holders’ option, is redeemable in cash upon maturity at December 31, 2014, or convertible into shares of common stock.
	The 2012 Convertible Notes have an anti-dilution provision that results in an embedded conversion feature that has been accounted for as a derivative. The fair value as of June 30, 2014 was determined using the following inputs: stock price of $2.25, 50% volatility, a 0.50 year term and a risk-free interest rate of 0.11%. The estimated fair value of the conversion feature as of June 30, 2014 and December 31, 2013 was $0.1 million and $0.5 million, respectively, which has been recorded as a derivative liability in the consolidated balance sheets. These unobservable inputs represent a Level 3 measurement within the fair value hierarchy. The estimated fair value of the conversion feature is revalued on a monthly basis and any resulting increases or decreases in the estimated fair value are recorded within other income (expense).
	During 2013, the Company issued 486,923 common shares upon the conversion of $1.25 million of the principal balance of the 2012 Convertible Notes into common stock. $0.7 million of the derivative liability was re-classified to additional paid in capital upon conversion, and $0.2 million of the debt discount was credited to additional paid in capital.
	The Company’s convertible notes payable balance consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Principal amount of convertible notes	1,225			2,750
	Less: unamortized debt discount	(44		)	(150		)
	Total short-term debt	$	1,181		$	2,600
	The Company recognized interest expense related to its convertible notes payable of $0.2 million for each of the six months ended June 30, 2014 and 2013.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	The following table summarizes the Company’s liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy contained in accounting guidance for fair value measurements and disclosures (in thousands):
		Fair Value			Quoted Market Prices		Significant Other		Significant
					for Identical Assets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	As of June 30, 2014
	Derivative liability related to 2012 Convertible Notes	$	95		$	—	$	—	$	95
	As of December 31, 2013
	Derivative liability related to 2012 Convertible Notes	$	517		$	—	$	—	$	517
	Derivative Instruments
	The Company’s conversion derivative related to its 2012 Convertible Notes is classified as Level 3 since the liability is not actively traded and is valued using significant unobservable inputs. Significant inputs to this model were the Company’s stock price, conversion price, risk free interest rate, and expected volatility of the Company’s stock price. Changes in fair value are recorded in the statement of operations as other income (expense). A portion of the notes were converted during 2013 and the associated derivative liability was reclassified to stockholders’ equity.
	The following table summarizes the continuing operations activity of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 inputs) (in thousands):
	Balance as of December 31, 2013	$	517
	Change in fair value measurement of derivative liability in connection with 2012 Convertible Notes, included in other expense	(422		)
	Balance as of June 30, 2014	$	95

Litigation

Litigation	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Litigation	'
	Litigation
	The Company is a party to the following litigation, as well as certain other litigation that the Company does not deem material or that, from time to time, arises in the ordinary course of business. The Company intends to vigorously defend its interests in these matters. The Company expects that the resolution of these matters will not have a material adverse effect on its business, financial condition or results of operations. However, due to uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.
	Versailles Civil Court Summons
	On April 25, 2013, certain of the Company’s former French Subsidiaries entered into a judicial liquidation procedure as a result of a decrease in the unit’s operating performance resulting from the then recently enacted pricing policies affecting drug reimbursement in France, the subsequent related loss or interruption of certain contract sales agreements and in this context, the Company’s decision to cease financing its former French Subsidiaries.
	In June 2013, the Civil Court authorized the French Works Council to deliver a writ of summons to the Company for a hearing in the Civil Court in September 2013. In the summons, it was claimed that the Company was the co-employer of the individuals working for Scomedica SAS and that, as such, was liable for the financing of a job protection plan. The summons sought €4.1 million ($5.6 million as of June 30, 2014) from the Company. During the second quarter of 2014, the Parties to the GSA as well as each of the former French Subsidiaries’ employees waived all claims they had asserted or could have asserted against the Company related to the liquidation and reorganization of the French Subsidiaries. In June 2014, consistent with the GSA, the Works Council withdrew its previously submitted €4.1 million claim in the Civil Court, all parties accepted the withdrawal and the Civil Court judge closed the discussions between all parties. The final step, which is perfunctory in nature, is scheduled on October 7, 2014, with a written judgment expected approximately six weeks later, during which the Civil Court is to acknowledge the dismissal of the claim and the closure of the litigation. Given the existence of the aforementioned ratified GSA, the accepted withdrawal and the closure of the discussions by the Civil Court judge, it is concluded that the Company is relieved of all claims previously asserted by the French Works Council.
	See Note 3 for additional details on the conclusion of the Versailles Civil Court Summons.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Financial Statement Presentation	'
	Financial Statement Presentation
	The accompanying unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in Apricus Biosciences, Inc.’s (the “Company”) Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2014. The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying consolidated financial statements. Certain prior year items in the statement of cash flows have been reclassified to conform to the current year presentation. The consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The consolidated financial statements (unaudited) for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Liquidity	'
	Liquidity
	The accompanying unaudited consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $269.5 million as of June 30, 2014, recorded a net loss of approximately $1.4 million for the six months ended June 30, 2014, and has principally been financed through the public offering of the Company’s common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development. Funds raised in recent periods from the sale of common stock include approximately $15.8 million from the Company’s May 2013 follow-on public offering. Additionally, the Company raised approximately $2.2 million during the six months ended June 30, 2014 from the sale of common stock via its “at-the-market” (“ATM”) stock selling facility and approximately $0.8 million from this facility in 2013. In 2013, the Company divested certain non-core assets for net cash consideration of approximately $8.0 million primarily related to the sale of its New Jersey facility, the sale of its Totect® assets, and the sale of securities from an investment previously held. The Company also received $1.8 million in 2013 as an up-front payment from Laboratoires Majorelle (“Majorelle”). These and other cash-generating activities should not necessarily be considered an indication of the Company’s ability to raise additional funds in the future.
	The Company’s cash and cash equivalents as of June 30, 2014 were approximately $17.4 million. During the first half of 2014, the Company received an up-front license payment of $2.0 million from Hexal AG, a regulatory milestone payment of $0.2 million from Majorelle related to marketing approval obtained in France for Vitaros®, an up-front license payment of $2.5 million from Recordati Ireland Ltd. (“Recordati”) and $0.7 million from Samm Solutions, Inc. dba BioTox Sciences (“BioTox”). These cash inflows were offset by principal cash payments of approximately $1.525 million plus accrued interest made by the Company to holders of its convertible notes who exercised their redemption rights in the second quarter of 2014.
	Based upon its current business plan, the Company believes it has sufficient cash to fund its on-going operations into the second quarter of 2015. The Company expects to have net cash outflows from operations during the remainder of 2014 as it continues to support the market approvals and partner commercialization plans for Vitaros®, further develops Room Temperature Vitaros® and initiates a Phase 2a development program for RayVa™, its product candidate for the treatment of Secondary Raynaud’s Phenomenon. During the fourth quarter of 2014, the Company expects to make the final principal payments of $1.225 million of convertible notes (see Note 5), which mature on December 31, 2014. The Company expects the majority of its cash inflows from operations during the remainder of 2014 will be from licensing, and milestone revenues received from existing and potentially new commercial partners for licenses granted for Vitaros®. The Company also expects cash inflows to include royalty payments from the sale of Vitaros® by the Company’s partners in approved territories, sales of which began late in the second quarter of 2014 in the United Kingdom. The initial royalty amounts are not expected to be significant in the second half of 2014 as the product sales by partners will only be initiated during the second half of 2014.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity or convertible debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
Segment Information	'
	Segment Information
	The Company operates under one segment which designs and develops pharmaceutical products using its NexACT® technology.
Net Income Per Share	'
	Net Income Per Share
	The Company reports diluted net income per share under the treasury stock method. Basic net income per share under the treasury stock method is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares may include stock options, restricted stock or shares related to convertible notes. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation expense and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and can be applied either prospectively or retrospectively to all awards outstanding as of the beginning of the earliest annual period presented as an adjustment to opening retained earnings. Early adoption is permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in the way it expects to be entitled for the transfer of promised goods or services to customers.  This ASU will replace most of the existing revenue recognition requirements in U.S. GAAP when it becomes effective.  This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted.  The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This ASU raises the threshold for a disposal to qualify as discontinued operations and requires new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation.  Under the new standard, companies report discontinued operations when they have a disposal that represents a strategic shift that has or will have a major impact on operations or financial results.  This update will be applied prospectively and is effective for annual periods, and interim periods within those years, beginning after December 15, 2014.  Early adoption is permitted provided the disposal was not previously disclosed.  This update will not have a material impact on the Company's reported results of operations and financial position.
Inventory	'
	Inventories are valued at the lower of cost (first-in, first-out) or market value (net realizable value) considering excess and obsolete inventory based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life and assumptions about the likelihood of obsolescence.

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Basic and Diluted Earnings Per Share	'
	he following table sets forth the computation of basic and diluted EPS for the three and six months ended June 30, 2014 and 2013 (in thousands, except per share data):
		Three Months Ended June 30,					Six Months Ended June 30,
		2014		2013			2014			2013
	Basic net income (loss) per share
	Net income (loss) allocated to common stockholders	$	1,877	$	(3,935	)	$	(1,385	)	$	(12,608	)
	Weighted average common shares outstanding- basic	37,901		32,825			37,886			31,509
	Net income (loss) per share- basic	$	0.05	$	(0.12	)	$	(0.04	)	$	(0.40	)
	Diluted net income (loss) per share
	Net income (loss) allocated to common stockholders	$	1,877	$	(3,935	)	$	(1,385	)	$	(12,608	)
	Weighted average common shares outstanding- basic	37,901		32,825			37,886			31,509
	Dilutive securities	6		—			—			—
	Weighted average common shares outstanding- diluted	37,907		32,825			37,886			31,509
	Net income (loss) per share- diluted	$	0.05	$	(0.12	)	$	(0.04	)	$	(0.40	)

Ceased_Operations_and_Disconti1

Ceased Operations and Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Schedule of Gain on Deconsolidation of Former French Subsidiaries	'
	As a result, during the second quarter of 2014, the Company released the approximate $2.8 million liability previously recorded in connection with the deconsolidation of the former French Subsidiaries and recognized approximately $0.8 million as a gain on deconsolidation as follows:
	Release of deconsolidation liability	$	2.8
	Less: Payments made by Majorelle and recorded as settlement payment charge by the Company	(2.0		)
	Gain on deconsolidation of former French Subsidiaries	$	0.8

Other_Financial_Information_Ta

Other Financial Information (Tables)	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Summary of Inventory	'
	Inventory is comprised of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	160	$	209
	Work in process	116		127
	Finished goods	101		—
	Inventory, net	$	377	$	336
Summary of Accrued Expenses	'
	Accrued expenses are comprised of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Professional fees	$	692	$	997
	Outside research and development services	474		298
	Deferred compensation	175		184
	Environmental remediation services	146		168
	Other	320		472
		$	1,807	$	2,119

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Convertible Notes Payable	'
	The Company’s convertible notes payable balance consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Principal amount of convertible notes	1,225			2,750
	Less: unamortized debt discount	(44		)	(150		)
	Total short-term debt	$	1,181		$	2,600

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Liabilities that Require Fair Value Measurement on a Recurring Basis and Input Levels	'
	The following table summarizes the Company’s liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy contained in accounting guidance for fair value measurements and disclosures (in thousands):
		Fair Value			Quoted Market Prices		Significant Other		Significant
					for Identical Assets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	As of June 30, 2014
	Derivative liability related to 2012 Convertible Notes	$	95		$	—	$	—	$	95
	As of December 31, 2013
	Derivative liability related to 2012 Convertible Notes	$	517		$	—	$	—	$	517
Summary of Continuing Operations Activity of Liabilities Measured at Fair Value on a Recurring Basis	'
	The following table summarizes the continuing operations activity of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 inputs) (in thousands):
	Balance as of December 31, 2013	$	517
	Change in fair value measurement of derivative liability in connection with 2012 Convertible Notes, included in other expense	(422		)
	Balance as of June 30, 2014	$	95

Basis_of_Presentation_Addition

Basis of Presentation Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2014

Nov. 30, 2013

Jun. 30, 2014

Jan. 31, 2014

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

31-May-13

Jun. 30, 2014

Dec. 31, 2013

Segment

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Recordati License Agreement

Recordati License Agreement

Samm Solutions, Inc. dba BioTox Sciences

Follow-on public offering

At-the-market stock sales

At-the-market stock sales

Basis of Presentation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Retained earnings (accumulated deficit)

($269,451,000)

'

'

($269,451,000)

'

($268,066,000)

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

1,877,000

'

-3,935,000

-1,385,000

-12,608,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

'

'

'

2,176,000

16,612,000

'

'

'

'

'

'

'

'

'

'

15,800,000

2,200,000

800,000

Proceeds from the sale of assets

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Cash received for upfront payment and approval in France

'

'

'

'

'

'

'

200,000

1,800,000

200,000

2,000,000

2,000,000

2,500,000

2,500,000

700,000

'

'

'

Cash and cash equivalents

17,420,000

'

24,764,000

17,420,000

24,764,000

21,405,000

15,130,000

'

'

'

'

'

'

'

'

'

'

'

Principal payments to holders of convertible notes

1,525,000

'

'

1,525,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes

$1,225,000

'

'

$1,225,000

'

$2,750,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basis_of_Presentation_Earnings

Basis of Presentation Earnings Per Share (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Accounting Policies [Abstract]	'	'	'	'	'	'
Net loss	$1,877	'	($3,935)	'	($1,385)	($12,608)
Basic net income (loss) per share	'	'	'	'	'	'
Weighted average shares outstanding, basic (in share)	37,901,000	37,901,000	32,825,000	32,825,000	37,886,000	31,509,000
Net income (loss) per share from continuing operations, basc (USD per share)	$0.03	'	($0.12)	'	($0.06)	($0.35)
Net income (loss) per share, basic (USD per share)	'	$0.05	'	($0.12)	($0.04)	($0.40)
Diluted net income (loss) per share	'	'	'	'	'	'
Dilutive securities	6,000	'	0	'	0	0
Weighted average number of shares outstanding, diluted (in shares)	37,907,000	'	32,825,000	'	37,886,000	31,509,000
Net income (loss) per share from continuing operations, diluted (USD per share)	$0.03	'	($0.12)	'	($0.06)	($0.35)
Net income (loss) per share, diluted (USD per share)	$0.05	'	($0.12)	'	($0.04)	($0.40)
Stock Compensation Plan	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'
Securities excluded from computation of EPS	3,200,000	'	'	'	'	'
Warrant	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'
Securities excluded from computation of EPS	6,200,000	'	'	'	'	'
Convertible Debt Securities	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'
Securities excluded from computation of EPS	500,000	'	'	'	'	'

Licensing_and_Research_and_Dev1

Licensing and Research and Development Agreements - Additional Information (Detail)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

3 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Oct. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Aug. 01, 2014

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Nov. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

USD ($)

USD ($)

USD ($)

USD ($)

Abbott License Agreement

Abbott License Agreement

Abbott License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Takeda Agreement

Takeda Agreement

Takeda Agreement

deliverable

deliverable

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Additional Revenue Recognized

Maximum

Maximum

Maximum

Maximum

USD ($)

USD ($)

Maximum

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

Maximum

Maximum

USD ($)

Maximum

Maximum

USD ($)

USD ($)

USD ($)

EUR (€)

Subsequent Event

USD ($)

EUR (€)

USD ($)

EUR (€)

territory

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash received for upfront payment and approval in France

'

'

'

'

$2,500,000

'

'

'

$1,000,000

'

'

'

$700,000

'

'

$500,000

$2,000,000

$2,000,000

'

'

$200,000

'

$1,800,000

'

$200,000

'

'

$2,500,000

$2,500,000

'

'

'

'

'

'

Number of territories granted national phase approval (in territories)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

License revenue

5,454,000

637,000

5,454,000

669,000

'

2,500,000

'

'

700,000

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

1,000,000

'

'

Expected upfront license fees and milestone payments

'

'

'

'

'

'

13,200,000

'

'

6,500,000

4,750,000

'

'

500,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,300,000

34,650,000

Less: Amounts deferred pending completion of additional contract contingencies

'

'

'

'

'

'

'

300,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Future expected proceeds from sales milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,500,000

20,875,000

'

'

'

'

'

21,200,000

15,500,000

'

'

'

47,100,000

34,500,000

'

'

'

Future expected proceeds from regulatory milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

Future expected proceeds from commercial launch payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

1,000,000

'

'

'

'

'

License fees, expected future proceeds on marketing launch milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments made by Majorelle on behalf of the Company (May 2014)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

Fair value of license granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

License agreement refund

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

$1,000,000

'

'

'

'

'

'

'

'

'

'

Number of deliverables

2

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ceased_Operations_and_Disconti2

Ceased Operations and Discontinued Operations License Fee Revenue (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jan. 31, 2014	Dec. 31, 2013	Nov. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
					Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'	'	'	'	'
Cash received for upfront payment and approval in France	'	'	'	'	$200,000	'	$1,800,000	'	$200,000
Payments made by Majorelle on behalf of the Company (May 2014)	'	'	'	'	'	2,000,000	'	2,000,000	'
Less: Amounts deferred pending completion of additional contractual conditions	'	'	'	'	'	'	'	-1,000,000	'
License fee revenue	$5,454,000	$637,000	$5,454,000	$669,000	'	'	'	$3,000,000	'

Ceased_Operations_and_Disconti3

Ceased Operations and Discontinued Operations License Fee Revenue (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jan. 31, 2014	Dec. 31, 2013	Nov. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
					Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement	Majorelle License Agreement
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'	'	'	'	'
Cash received for upfront payment and approval in France	'	'	'	'	$200,000	'	$1,800,000	'	$200,000
Payments made by Majorelle on behalf of the Company (May 2014)	'	'	'	'	'	2,000,000	'	2,000,000	'
Less: Amounts deferred pending completion of additional contractual conditions	'	'	'	'	'	'	'	-1,000,000	'
License fee revenue	$5,454,000	$637,000	$5,454,000	$669,000	'	'	'	$3,000,000	'

Ceased_Operations_and_Disconti4

Ceased Operations and Discontinued Operations Discontinued Operations (Details) (USD $)	6 Months Ended		1 Months Ended	3 Months Ended	5 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2011	Jun. 30, 2014	31-May-14	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
			Sale Of Bio Quant Incorporated	Sale Of Bio Quant Incorporated	Sale Of Bio Quant Incorporated	Sale Of Bio Quant Incorporated	Sale Of Bio Quant Incorporated	Sale Of Bio Quant Incorporated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'
Proceeds from sale of subsidiary	$50,000	$105,000	$500,000	$600,000	$100,000	$700,000	$300,000	$300,000
Minimum receivable in sale of business	'	'	4,500,000	'	'	'	'	'
Entitled receivable per year, for sale of business	'	'	500,000	'	'	'	'	'
Gain on disposal of discontinued operations	'	'	'	$700,000	'	$700,000	'	'

Other_Financial_Information_In

Other Financial Information - Inventory (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Gross [Abstract]	'	'
Raw materials	$160	$209
Work in process	116	127
Finished goods	101	0
Inventory, net	$377	$336

Other_Financial_Information_Ac

Other Financial Information - Accrued Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Professional fees	$692	$997
Outside research and development services	474	298
Deferred compensation	175	184
Environmental remediation services	146	168
Other	320	472
Accrued expenses	$1,807	$2,119

Other_Financial_Information_Ad

Other Financial Information - Additional Information (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Restricted cash held in escrow	$0.30

Convertible_Notes_Payable_Addi

Convertible Notes Payable - Additional Information (Detail) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Debt Instrument	'	'	'
Principal amount of convertible notes	$1,225,000	'	$2,750,000
Issuance of common stock upon exercise of convertible notes (shares)	'	486,923	486,923
Principal balance of note converted into common stock	'	'	1,250,000
Derivative liability was re-classified as additional paid in capital upon conversion	'	'	700,000
Debt discount credited to statement of operations upon on conversion	'	'	200,000
Amortization of debt discount	200,000	100,000	'
Amended 2010 Convertible Notes	'	'	'
Debt Instrument	'	'	'
Convertible notes, conversion price (in USD per share)	$2.58	'	'
Convertible notes, coupon rate	7.00%	'	'
Convertible Note 2012	'	'	'
Debt Instrument	'	'	'
Stock price (in USD per share)	$2.25	'	'
Fair value assumption, volatility	50.00%	'	'
Fair value assumption, term (in years)	'6 months	'	'
Derivative liability related to 2012 Convertible Notes	100,000	'	500,000
Convertible Note 2012 | Fair Value, Inputs, Level 3	'	'	'
Debt Instrument	'	'	'
Risk adjusted annual interest rate	16.00%	'	'
Convertible notes, option to redeem	$1,525,000	'	'
Fair value assumption, risk-free interest rate	0.11%	'	'

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Principal amount of convertible notes	$1,225	$2,750
Less: unamortized debt discount	-44	-150
Total short-term debt	$1,181	$2,600

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary Of Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) (Recurring, USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability related to 2012 Convertible Notes	$95	$517
Quoted Market Prices for Identical Assets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability related to 2012 Convertible Notes	0	0
Significant Other Observable Inputs (Level 2)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability related to 2012 Convertible Notes	0	0
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability related to 2012 Convertible Notes	$95	$517

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary Of Activity In Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Balance as of December 31, 2013	$517
Change in fair value measurement of derivative liability in connection with 2012 Convertible Notes, included in other expense	-422
Balance as of June 30, 2014	$95

Litigation_Additional_Informat

Litigation - Additional Information (Details) (Scomedica)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
	USD ($)	EUR (€)
Commitments And Contingencies [Line Items]	'	'
Loss contingency, damages sought	$5.60	€ 4.10